ARTH ARCH THERAPEUTICS INC
- 1.050000
- +0.010000+0.96%
ARCH THERAPEUTICS INC News
ARCH THERAPEUTICS INC | 10-Q: Quarterly report
Arch Therapeutics to Present AC5 Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced
Arch Therapeutics Provides Year End Operational Update
FRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided
Arch Therapeutics Files to List Stock, Warrants on Nasdaq
Arch Therapeutics Files to List Stock, Warrants on Nasdaq
Arch Therapeutics Provides AC5 Commercialization Update
FRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics Completes Financing as Bridge to Uplisting
FRAMINGHAM, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics to Present AC5 Advanced Wound System at 2023 Symposium on Advanced Wound Care ("SAWC")
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS reimbursement codeFRAMINGHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Arch Therap
Dedicated HCPCS Billing Code for Arch Therapeutics' AC5 Advanced Wound System Now In Effect
FRAMINGHAM, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics' AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code From The Centers for Medicare & Medicaid Services
FRAMINGHAM, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities
FRAMINGHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Announces 1-for-200 Reverse Stock Split
Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection With Application for Uplisting to a National Exchange
FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics' AC5® Advanced Wound System
FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today
Arch Therapeutics’ AC5® Advanced Wound System to Be Presented With Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
Awarded Highest Scoring Poster Abstract in Case Series / Study CategoryFRAMINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a markete
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
Significant Milestone in Commercialization Plan Expected to Drive Sales MomentumFRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound HealingFRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:
Arch Therapeutics Announces Intent to Uplist From OTC to a National Exchange
Consistent with Long-Term Strategic Plan to Increase Capital Market Visibility and Enhance Access to Growth CapitalFRAMINGHAM, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQ
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
Expected to Accelerate Sales Opportunities in Doctor's Office and Wound ClinicsFRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System
HCPCS Code May Support Product Differentiation and Enhance Existing Sales Opportunities Under New CMS 2022 Billing and Reimbursement Pathway for Synthetic Skin SubstitutesFRAMINGHAM, Mass., Sept. 01,
Analysis
Price Target
No Data
